Drug Search Results
More Filters [+]


Alternative Names: alefacept, amevive
Latest Update: 2023-08-23
Latest Update Note: Clinical Trial Update

Product Description

Alefacept (Amevive®, Astellas Pharma US, Inc.) is a full dimeric human fusion protein, which consists of an extracellular portion of the human leukocyte function antigen-3 (LFA-3) fused to the Fc portion of immunoglobulin G1. Alefacept is the first biological agent approved by the US Food and Drug Administration (FDA) for the treatment of moderate to severe chronic plaque psoriasis. It is a full human fusion protein binding to CD2 on T cells. With its dual mechanism of action, alefacept blocks the interaction between the leukocyte-function-associated antigen (LFA)-3 and CD2 and thereby impedes the activation and proliferation of T cells. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2386357/)

Mechanisms of Action: LFA3 Inhibitor,CD2 Inhibitor

Novel Mechanism: No

Modality: Fusion Protein

Route of Administration: Intramuscular,Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Canada | Chile | Peru | United Kingdom

Approved Indications: None

Known Adverse Events: None

Company: Astellas Pharma
Company Location: NEW YORK NY 10005
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Alefacept

Countries in Clinic: Australia

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Crohn Disease



Trial Status


Primary Completion Date

Probability of Success



Not yet recruiting

Crohn Disease


Recent News Events